Adial Pharmaceuticals, Inc.
ADIL
$3.11
-$0.32-9.20%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.12M | 5.06M | 5.18M | 5.06M | 5.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.85M | 8.30M | 8.71M | 8.28M | 8.13M |
| Operating Income | -7.85M | -8.30M | -8.71M | -8.28M | -8.13M |
| Income Before Tax | -8.05M | -8.45M | -8.95M | -13.20M | -13.03M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.05 | -8.45 | -8.95 | -13.20 | -13.03 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -15.90K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.05M | -8.45M | -8.95M | -13.20M | -13.05M |
| EBIT | -7.85M | -8.30M | -8.71M | -8.28M | -8.13M |
| EBITDA | -7.85M | -8.30M | -8.71M | -8.28M | -8.13M |
| EPS Basic | -23.22 | -30.59 | -40.67 | -86.97 | -99.46 |
| Normalized Basic EPS | -26.47 | -31.07 | -37.37 | -66.31 | -62.06 |
| EPS Diluted | -23.22 | -30.59 | -40.67 | -86.97 | -99.46 |
| Normalized Diluted EPS | -26.47 | -31.07 | -37.37 | -66.31 | -62.06 |
| Average Basic Shares Outstanding | 1.83M | 1.18M | 918.90K | 775.50K | 612.30K |
| Average Diluted Shares Outstanding | 1.83M | 1.18M | 918.90K | 775.50K | 612.30K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |